Has Alison Lovkay received payments from drug or device companies?

Yes. Drug and device makers reported $5,671 in general payments to Alison Lovkay across 254 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alison Lovkay did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alison Lovkay come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alison Lovkay

Physician Assistant · Charlotte, NCNPI 1205329026

Payments from drug & device makers

$5,671in general payments, 2019–2025

Across 254 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Otsuka America Pharmaceutical, Inc.$577
Lundbeck LLC$431
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$430
Alkermes, Inc.$400
Tris Pharma Inc$361
plus $2K from 15 others

What the payments were for

Food & beverage$5,671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	78	$1,242
Otsuka America Pharmaceutical, Inc.	27	$577
Lundbeck LLC	19	$431
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	16	$430
Alkermes, Inc.	11	$400
Tris Pharma Inc	16	$361
Supernus Pharmaceuticals, Inc.	3	$310
Johnson & Johnson	8	$251
Takeda Pharmaceuticals U.S.A., Inc.	13	$239
Axsome Therapeutics, Inc.	10	$221
Neurocrine Biosciences, Inc.	7	$219
Teva Pharmaceuticals USA, Inc.	8	$200
Ironshore Pharmaceuticals Inc.	8	$164
Noven Therapeutics, LLC	6	$108
Sunovion Pharmaceuticals Inc.	6	$98
Bioxcel Therapeutics, Inc.	2	$90
Corium, LLC	4	$90
Idorsia Pharmaceuticals US Inc	5	$88
Vanda Pharmaceuticals Inc.	3	$85
Merck	2	$34
Neos Therapeutics, LP	2	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYBALVI$897
VRAYLAR$339
QELBREE$273
CAPLYTA$125
AUSTEDO$112

How this compares

$5,671 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RexultiBrexpiprazole	17	$53,807
Oxcarbazepine	13	$1,109
Trazodone Hcl	36	$807
Duloxetine Hcl	12	$757
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	16	$746
Bupropion Hcl SrBupropion Hcl	16	$506
Bupropion XlBupropion Hcl	21	$427
Propranolol Hcl	27	$371
Venlafaxine Hcl ErVenlafaxine Hcl	14	$328
Lamotrigine	31	$229
Clonazepam	41	$203
Hydroxyzine Hcl	21	$193
Buspirone Hcl	18	$184
Gabapentin	17	$182
Sertraline Hcl	27	$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti	$577	$53,80717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

Rachel HolzhauerCharlotte$739K
Amber BlairCharlotte$551K
Kristin CabedaCharlotte$135K
Meghan EmigCharlotte$124K
Juleidy TurnipseedCharlotte$84K
Erin SiceloffCharlotte$50K
Ronald RodriguezCharlotte$31K
Lamiaa TolbaCharlotte$29K
Sanaya GandhiCharlotte$29K
Jacqueline LeyrerCharlotte$24K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →